Targeted cancer therapy trial seeks to control advanced tumors

NCT ID NCT07196644

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This study is testing an investigational drug called telisotuzumab adizutecan for people with advanced solid tumors that have a specific genetic feature called MET amplification. The main goals are to see how safe the drug is and whether it can shrink or control the tumors. About 125 participants aged 12 and older will receive the drug by IV infusion over a 5-year study period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS HARBORING MET AMPLIFICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Duke Cancer Institute /ID# 275604
RECRUITING

Durham, North Carolina, 27710, United States
Florida Cancer Specialists - North /ID# 277137
RECRUITING

St. Petersburg, Florida, 33705, United States
Hadassah Medical Center-Hebrew University /ID# 274343
RECRUITING

Jerusalem, 91120, Israel
Hokkaido University Hospital /ID# 276333
RECRUITING

Sapporo, Hokkaido, 060-8648, Japan
Kyoto University Hospital /ID# 276398
RECRUITING

Kyoto, Kyoto, 606-8507, Japan
Kyushu University Hospital /ID# 276302
RECRUITING

Fukuoka, Fukuoka, 812-8582, Japan
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999
RECRUITING

New York, New York, 10065, United States
Nagoya University Hospital /ID# 276336
RECRUITING

Nagoya, Aichi-ken, 466-8560, Japan
National Cancer Center Hospital /ID# 276297
RECRUITING

Chuo-Ku, Tokyo, 104-0045, Japan
Northwestern University Feinberg School of Medicine /ID# 276436
RECRUITING

Chicago, Illinois, 60611-2927, United States
Okayama University Hospital /ID# 276299
RECRUITING

Okayama, Okayama-ken, 700-8558, Japan
Rabin Medical Center. /ID# 274341
RECRUITING

Petah Tikva, 4941492, Israel
START Midwest /ID# 276603
RECRUITING

Grand Rapids, Michigan, 49546, United States
Samsung Medical Center /ID# 275705
RECRUITING

Seoul, Seoul Teugbyeolsi, 06351, South Korea
Seoul National University Hospital /ID# 275703
RECRUITING

Seoul, Seoul Teugbyeolsi, 03080, South Korea
South Texas Accelerated Research Therapeutics (START) /ID# 276608
RECRUITING

San Antonio, Texas, 78229, United States
Start Mountain Region /ID# 276607
RECRUITING

West Valley City, Utah, 84119, United States
Tel Aviv Sourasky Medical Center /ID# 274344
RECRUITING

Tel Aviv, Tel Aviv, 6423906, Israel
The Chaim Sheba Medical Center /ID# 274342
RECRUITING

Ramat Gan, Tel Aviv, 5265601, Israel
Tohoku University Hospital /ID# 276344
RECRUITING

Sendai, Miyagi, 980-8574, Japan
University of Chicago Medical Center /ID# 275342
RECRUITING

Chicago, Illinois, 60637, United States
Valkyrie Clinical Trials /ID# 275547
RECRUITING

Los Angeles, California, 90067, United States
Yale University School of Medicine /ID# 275978
RECRUITING

New Haven, Connecticut, 06510, United States
Yonsei University Health System Severance Hospital /ID# 276184
RECRUITING

Seoul, Seoul Teugbyeolsi, 03722, South Korea

Conditions

Explore the condition pages connected to this study.

SOLID TUMORS HARBORING MET AMPLIFICATION